Status:
COMPLETED
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Brief Summary
This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatmen...
Detailed Description
This is a prospective, non-blinded, multi-arm study. Patients at 18 - 70 years old with liver cancer will be enrolled. The approach is to identify novel proteomic biomarkers for HCC patients treated ...
Eligibility Criteria
Inclusion
- Ability to understand and the willingness to sign a written informed consent.
- Male or female aged 18-70years.
- Diagnosed with primary or metastatic liver cancer.
- Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care.
Exclusion
- Subjects who have received chemotherapy, radiation or surgery for HCC.
Key Trial Info
Start Date :
November 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 23 2025
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04459468
Start Date
November 4 2022
End Date
September 23 2025
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390